Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research


News Release: The Government of Canada invests over $21M in innovative health research ]

Through new CIHR funding, researchers will undertake innovative biomedical and clinical HIV vaccine research projects in new areas of investigation or take previous discoveries in new directions; promote the development and testing of novel HIV vaccine research tools and methodologies; and support high-risk HIV vaccine research projects with the potential for high impact, breakthrough and/or transformative advances.

A total of ten researchers and two new investigators from across the country were awarded $2.9M dollars for the following projects:

Researcher Institution Project Title Amount
Dr. Petronela Ancuta Centre hospitalier de l'Université de Montréal (CHUM) Targeting mTOR to restore mucosal immunity toward remission in HIV-infected individuals $250,000
Dr. Eric Arts University of Western Ontario Developing the ACT-VEC as an HIV therapeutic vaccine and cure approach $250,000
Dr. Dimitrios Dikeakos University of Western Ontario Nef Inhibitors as Adjuvants Towards a Cure $247,755
Dr. Jérôme Estaquier Université Laval Role of follicular CD8 T cells in the control of HIV/SIV mucosal immunity. $250,000
Dr. Daniel E Kaufmann Centre hospitalier de l'Université de Montréal (CHUM) Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens $249,994
Dr. Charu Kaushic McMaster University Improving vaginal health to decrease biological risk of HIV-1 infection in Canadian ACB women $250,000
Dr. Denis Leclerc Université Laval Adjuvantization of SIV antigens using a novel toll like receptor 7 (TLR7) agonist: A proof of concept in non-human primate. $250,000
Dr. Lyle R Mckinnon University of Manitoba Impact of Vedolizumab on immune cell homing to the female reproductive and gastrointestinal mucosa $249,460
Dr. Mario A Ostrowski University of Toronto Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies $250,000
Dr. Jean-Pierre Routy Research Institute of the McGill University Health Centre Locking out HIV from CD4 T cells: A pilot study of the impact of anti a4b7 antibody (vedolizumab) on viral control following analytical treatment interruption $247,650
Adam Burgener University of Manitoba Mechanisms of metaproteome factors in HIV infection risk in young women $249,888
Ruey-Chyi University of Manitoba Elucidating the role of cell homing pathways in controlling endothelial cell-mediated enhancement of resting CD4+ T cell infection by HIV $206,600

Page details

Date modified: